title: Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
abstract: Cardiac arrhythmias frequently respond only to drugs that have as their predominant electrophysiologic effect the prolongation of repolarization and refractoriness. According to the Singh-Vaughan Williams classification, these drugs are known as class III agents. In the last few years, interest has increased in the development of class III antiarrhythmic drugs as alternatives to sodium channel blocking agents, which mainly affect cardiac conduction. Much of this interest results from a perceived danger of using drugs with sodium channel blocking properties, particularly in patients with ischemic heart disease, based on the results of the Cardiac Arrhythmia Suppression Trial (CAST) and several other trials. This article is a review of the pharmacology, including the pharmacokinetics and pharmacodynamics, of the most commonly used and investigated class III antiarrhythmic drugs. As will be seen from the discussion, each of these drugs has novel pharmacology that makes it applicable in specific clinical situations. Their putative effects on various arrhythmogenic mechanisms and their efficacy in treating specific target arrhythmias will be addressed.
authors.affiliation: Division of Cardiovascular Diseases, Lankenau Hospital and Medical Research Center, Wynnewood, Pennsylvania 19096, USA.
authors.forename: P R
authors.initials: PR
authors.lastname: Kowey
authors.forename: R A
authors.initials: RA
authors.lastname: Marinchak
authors.forename: S J
authors.initials: SJ
authors.lastname: Rials
authors.forename: D
authors.initials: D
authors.lastname: Bharucha
mesh_terms: D000638:Amiodarone / Q000493:pharmacokinetics / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001949:Bretylium Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D010627:Phenethylamines / Q000493:pharmacokinetics / Q000627:therapeutic use; D013015:Sotalol / Q000493:pharmacokinetics / Q000627:therapeutic use; D013449:Sulfonamides / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D010627:Phenethylamines; D013449:Sulfonamides; C067192:ibutilide; D013015:Sotalol; D000638:Amiodarone; C063533:dofetilide; C045166:bretylium